European medicines agency recommends marketing approval of gobivaz®, alvotech's proposed biosimilar to simponi® (golimumab) with advanz pharma as commercialization partner

Reykjavik,  iceland and london, uk (september 22, 2025) — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma holdco limited (“advanz pharma”), a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending approval for gobivaz®, alvotech's proposed biosimilar to simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases.
ALVO Ratings Summary
ALVO Quant Ranking